Investors

Overview

Corporate Profile

Gamida Cell is an advanced cell therapy company committed to finding cures for patients with cancer and other serious diseases. We harness our NAM-enabled technology platform to create therapies with the potential to improve the course of cancer care.

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Latest News

View All
Sep 19, 2022

Gamida Cell Appoints Abigail L. Jenkins as President and Chief Executive Officer, Bringing Broad Leadership Experience in Commercializing Innovative Therapies

Read More
Sep 12, 2022

Gamida Cell Presents Data Demonstrating the Impact of Transplantation with Omidubicel for Patients with Hematologic Malignancies at 2022 Cord Blood Connect Meeting

Read More
Aug 15, 2022

Gamida Cell Reports Second Quarter 2022 Financial Results and Provides Company Update

Read More
Aug 10, 2022

Gamida Cell Announces Dosing of First Patient in Company-Sponsored Phase 1/2 Study of NK Cell Therapy Candidate GDA-201

Read More
Aug 08, 2022

Gamida Cell Announces the Date of Its Second Quarter 2022 Financial Results and Webcast

Read More
Aug 01, 2022

Gamida Cell Announces FDA Acceptance of Biologics License Application for Omidubicel with Priority Review

Read More
Jun 13, 2022

Gamida Cell to Present Corporate Highlights at the JMP Securities Life Sciences Conference

Read More
Jun 10, 2022

Gamida Cell Appoints Ivan M. Borrello, M.D., Expert in Immuno-Oncology, Cell Therapies, and Bone Marrow Transplant to Board of Directors

Read More
Jun 02, 2022

Gamida Cell Completes Rolling Biologics License Application Submission to the FDA for Omidubicel

Read More
Jun 01, 2022

Gamida Cell to Present Corporate Highlights at the Jefferies Healthcare Conference

Read More
Jun 01, 2022

Gamida Cell Announces Opening to Enrollment of Company-Sponsored Phase 1/2 Study of NK Cell Therapy Candidate GDA-201

Read More
May 17, 2022

Gamida Cell to Present Corporate Highlights at the H.C. Wainwright Global Life Sciences Conference

Read More
May 10, 2022

Gamida Cell Reports First Quarter 2022 Financial Results and Provides Company Update

Read More
May 05, 2022

Gamida Cell Presents New Data from NAM-Enabled Genetically Modified Natural Killer (NK) Pipeline at International Society for Cell & Gene Therapy 2022

Read More
May 03, 2022

Gamida Cell Announces the Date of Its First Quarter 2022 Financial Results and Webcast

Read More
Apr 27, 2022

Gamida Cell Presents Updated One-Year Post-Transplant Follow Up Data from Phase 3 Study of Omidubicel at 2022 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR Tandem Meetings

Read More
Apr 26, 2022

Gamida Cell Announces FDA Clearance of IND and Removal of Clinical Hold for NK Cell Therapy Candidate GDA-201

Read More
Apr 25, 2022

Gamida Cell Presents Updated Omidubicel Data During Best Abstract Award Session at 2022 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR Tandem Meetings

Read More
Apr 25, 2022

Gamida Cell Announces Results of New Health Economic and Outcome Study Reporting Improved Health Equity and Health Outcomes With Omidubicel at 2022 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR Tandem Meetings

Read More
Apr 07, 2022

Gamida Cell to Present Corporate Highlights and Participate in Panel Discussion at the Needham Healthcare Conference

Read More
Corporate Fact Sheet
Corporate Presentation